Purple Biotech Ltd.

_________ false


�� "�	2 352
KITOV PHARMA LTD
Corporation no: 520031238	10994
- - -


	Israel Securities Authority			Tel Aviv Stock Exchange		C004 ( Public )		Reported via MAGNA:	25/06/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-058657	Time of broadcast: 18:50 18:48:13

Immediate report on other matterDon't use this form if there is more adequate one


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2020 Commission File Number: 001-37643 KITOV PHARMA LTD. This Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of ADSs or warrants in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant�s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117 and 333-211477), the Registrant�s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant�s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant�s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant�s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant�s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant�s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327), the Registrant�s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333- 238229), and the Registrant�s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration file number 333-238481), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. �� 2020. �� "� �� , �� , �� , ��
Attached file ea123437a-6k_kitovpharmaEDGAR4_isa.pdf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2020 Commission File Number: 001-37643 KITOV PHARMA LTD. This Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of ADSs or warrants in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant�s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117 and 333-211477), the Registrant�s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant�s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant�s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant�s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant�s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant�s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327), the Registrant�s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333- 238229), and the Registrant�s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration file number 333-238481), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. �� 2020. �� "� �� , �� , �� , ��

Attached file ea123437a-6k_kitovpharmaEDGAR4_isa.pdf


The submission by the Company to the Israel Securities Authority and the Tel Aviv Stock Exchange of a copy of a Form 6-k originally submitted by the Company to the United States Securities Exchange Commission for the purposes of incorporating by reference certain documents exhibited to the Form 6-k into the Company's U.S. Registration Statements should not be deemed an admission by the Company that such submission is required of the Company under the Securities Law 5728-1968 and the Securities Regulations (Periodic and Immediate Reports of Foreign Corporation) 5761-2000, nor an admission by the Company that this submission is necessarily being delivered pursuant to the aforesaid laws and regulations.
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):


- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 23/06/2020
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101 , Israel Tel: 03-9333121 , Fax: 03-5097196
E-mail address: [email protected] Company site: www.kitovpharma.com

Previous names of reporting entity: KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,

Name of the Signatory: BEN-TZVI ABRAHAM SHLOMO Position of Signatory in the reporting corporation: Lawyer/ Legal Counsel Name of Employer Company: ABZ Law Office
Address: Yad Harutzim 15 , Jerusalem 9342152 Telephone: 079-5722070 Facsimile: 079-5722206 E-mail: [email protected] 1
Israel

AI Terminal

7004_rns_2020-06-25_bb6495db-a6a5-433a-9a04-90bd93bf904d.htm

More from Purple Biotech Ltd.

Talk to a Data Expert